Medtech

Datametrex AI subsidiary Medi-Call partners with Lucira Health for telehealth services

Lucira uses its app and website to direct patients to Medi-Call’s telehealth services after a positive result
The post Datametrex AI subsidiary Medi-Call…

Published

1 year ago

January 4, 2023

This article was originally published by Mugglehead

Medi-Call, the telehealth arm of Datametrex AI (TSXV: DM) (FSE: D4G) (OTC: DTMXF), partnered with Lucira Health to provide telehealth services for Lucira clients.

Lucira’s product is a do-it-yourself at-home diagnostic testing device for COVID-19 and influenza A and B strains that’s been approved by Health Canada. Lucira uses its app and website to direct patients to Medi-Call’s telehealth services, which will give Medi-Call more access to patients.

“Being represented on the Lucira platform increases Medi-Call’s exposure to more potential patients and business,” said Marshall Gunter, CEO of Datametrex AI.

The test works in 30 minutes or less and tells users whether they have COVID-19 or the flu. In the event of a positive result, Lucira’s platform will direct users to Medi-Call’s telehealth services to see a doctor or get a prescription.

Lucira’s home test finds the flu and COVID-19

Health Canada designated Lucira the first COVID-19 and flu self-test in 2022, but the company has been around since 2013. The company’s mission is to change the way people manage their health.

Its testing tech provides results as fast as 11 minutes for a positive result and 30 for a negative. It involves using one shallow nasal swab, and can test for all variants of COVID-19 and influenza A and B. Additionally, Health Canada authorized its use for ages 2 and up.

Medi-Call is a subscription-based mobile app using a software as a service approach to connect patients and doctors. The company’s goal is to simplify healthcare for patients by making mobile healthcare services accessible from their device. The app also provides health services like general and preventative care, urgent care, mental health services and prescriptions. It also helps resolve accessibility issues for patients living in rural or isolated communities.

Lucira’s test is a molecular, nucleic acid amplification test (NAAT) which can be taken at home. The self-tests have analytical sensitivity, allowing the tech to detect viruses with accuracy rates between 98 and 99 per cent, compared to lab-based polymerase chain reaction (PCR) tests. The company has also run tests on its product multiple times and verified these percentages.